Screener
Crinetics Pharmaceuticals CRNX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
| Other comprehensive income (loss): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's business segments — net loss?
- Crinetics Pharmaceuticals (CRNX) reported business segments — net loss of -$127.85M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — net loss changed year-over-year?
- Crinetics Pharmaceuticals's business segments — net loss decreased by 32.1% year-over-year, from -$96.77M to -$127.85M.
- What does business segments — net loss mean?
- Represents the bottom-line financial result where total expenses exceed total revenues for the reporting period. For a clinical-stage pharmaceutical company, this metric reflects the significant investment in research and development and commercial infrastructure relative to current product sales. It serves as a primary indicator of the company's cash burn and financial sustainability.
Ask your AI about Crinetics Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude